Take­da scores FDA ap­proval for $400M col­orec­tal can­cer ther­a­py

Less than a year af­ter bet­ting $400 mil­lion cash on Hutchmed’s fruquin­tinib, Take­da has se­cured FDA ap­proval for the VEGF re­cep­tor ki­nase in­hibitor in pre­vi­ous­ly treat­ed metasta­t­ic col­orec­tal can­cer.

Fruza­qla, as the ther­a­py is called, is the first new “chemother­a­py-free treat­ment op­tion ap­proved for pa­tients in the US re­gard­less of bio­mark­er sta­tus in more than a decade,” Tere­sa Bitet­ti, pres­i­dent of the glob­al on­col­o­gy busi­ness unit at Take­da, said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER